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Immunisation against meningococcal meningitis has a long his-
tory, which has passed through several phases: the studies by 
Flexner, extraction of the polysaccharide capsule, the develop-
ment of monovalent and multivalent conjugate vaccines, the outer 
membrane vesicle vaccines up to the development of effective and 
safe vaccines for meningococcal B invasive disease through the 
application of the techniques of molecular biology and reverse 
vaccinology.
The new available vaccines are Bexsero® and Trumenba®. Bex-
sero® has been approved and is available in Europe, the USA, 
Canada, Australia and Chile, and is currently under review in 
Brazil for the prevention of MenB invasive disease in subjects ≥ 
2 months. 
Trumemba® is currently approved only in the USA, for use in ado-
lescents and young adults.
At present, the greatest obstacle to the extensive use of these vaccines 
in industrialised countries is the high cost and the need administer 
multiple doses in infants. However, in some European countries and 
in some Italian Regions, strategies (free and active call) to fight the 
disease through vaccination (Bexsero®) are already in place. 
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Summary
Introduction
Conjugate vaccines against Haemophilus influentiae 
type b, Streptococcus pneumoniae and Meningococcus 
C have dramatically reduced cases of bacterial menin-
gitis in the industrialised nations. However, meningitis 
type B continues to be a threat to children and adoles-
cents worldwide. 
Unlike other serogroups, Neisseria meningitidis B 
(MenB) disease cannot be prevented by polysaccha-
ride vaccines. The reason for this lies in the chemical 
structure of the MenB capsule, which contains units are 
identical to some human polysaccharides (human foetal 
neural cells) and, therefore, determine immunological 
tolerance [1]. Consequently, research into an effective 
MenB vaccine has focused on subcapsular antigens, 
outer membrane vesicles (OMVs). OMVs were suc-
cessfully used to control specific outbreaks. OMVs are 
proteoliposomes that contain several different molecu-
lar components out of which the porin protein, PorA, 
is the principle antigenic source of bactericidal antibod-
ies. The limitations of these vaccines are that effective-
ness tends to be limited to strains containing the same 
PorA protein (serosubtype-specific), limiting its use to 
strain-specific outbreaks and they often elicited a scant 
immune response in young children [2]. 
In the last years, the vaccine industry has overcome 
this difficulty, and a MenB multicomponent vaccine – 
4CMenB – Bexsero® – has been developed. This vac-
cine has been licensed in Europe and other developed 
countries for the prevention of MenB invasive disease 
in subjects ≥2 months. In addition, a vaccine containing 
two variants of factor H binding protein (fhbp) of the 
complement has been approved by the Food and Drug 
Administration in the USA (Trumemba®) for use in in-
dividuals 10 through 25 years of age.
These advances have prompted some authors to wonder 
whether we are witnessing “the beginning of the end for 
invasive MenB disease” [1].
In order to eliminate an infectious disease, the first es-
sential requirement is undoubtedly the availability of 
safe and effective vaccines. However, strategic planning 
of the application of the vaccines which have become 
available is equally important.
This overview examines the policies of vaccination with 
new meningococcal B vaccines, particularly 4CMenB, 
in Italy.
Natural history of MenB infections
Meningococci have their natural and unique survival 
niche in humans. This fundamental biological fact im-
plies that N. meningitis has acquired several mechanisms 
for cohabitation with the human organism [3]. Only in 
particular conditions of frailty of the human host or in 
certain environmental situations is the microorganism 
able to manifest its aggressiveness, leading to meningo-
coccal diseases and even death [4, 5]. 
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From sero-epidemiological studies [6, 7] we have learnt 
much about the biology of this microorganism. In the 
blood of infants, bactericidal antibodies against Neisse-
riae are present as a result of the passage of maternal 
antibodies through the placenta during pregnancy. How-
ever, as this protection wanes early, infants are soon ex-
posed to the risk of infection. Indeed, the percentage of 
infants and children who show bactericidal antibodies 
grows until the age of about four years. Subsequently, 
antibody titres decline until adolescence, before increas-
ing again. This pattern is in line with the fact that the two 
main peaks of morbidity of the disease are seen in sub-
jects under 4 years of age (particularly in infants under 1 
year) and in young adults. These epidemiological obser-
vations are of primary importance in understanding the 
spread of the microorganism in the environment around 
the infant and adolescent. The greatest risk to the infant 
is engendered by premature contact with virulent strains 
of N. meningitidis, as has been shown by mathematical 
modelling [8]. Indeed, the risk of MenB invasive disease 
has been calculated to be 400 times higher in such cases 
than in the case of non-early contact. 
The situation changes during adolescence, when a more 
promiscuous social life (kissing, sexual contact, fre-
quenting recreational premises such as pubs, etc) ex-
poses subjects to more frequent contact with the micro-
organism. Indeed, it is precisely in these subjects that 
Neisseriae find their ideal niches for survival, as demon-
strated by studies on carriers [9, 10].
Epidemiology of MenB infections
The distribution of the various serogroups of menin-
gococcal pathogens fluctuates considerable. However, 
serogroup B currently predominates over the other se-
rogroups in Europe, Australia, Canada and Japan. One 
reason for this predominance is attributable to extensive 
vaccination with conjugate vaccine against meningococ-
cal serogroup C [11-16]. Of a total of 3463 confirmed 
cases of invasive meningococcal disease (IMD) reported 
in 28 EU/EEA countries in 2012, 2078 were caused by 
serogroup B; this predominance of serogroup B was most 
pronounced in infants (83% of cases, 8.9 per 100,000) 
and 1-4-year-olds (9% of cases, 2.9 per 100,000) [17].
The Italian surveillance system of invasive bacterial 
infections detected 991 cases of invasive meningococ-
cal disease from 2007 to 2012, with an average of 165 
cases per year. Information on typing is available for 
764/991 cases (77.1%). Serogroup B was the most fre-
quent (455 cases), constituting 59.6% of the cases typed, 
followed by serogroup C (220 cases) and serogroup Y 
(59 cases). During the reporting period, a decrease was 
observed in cases of meningococcal B (from 81 cases 
in 2007 to 52 in 2012) and C (from 43 cases in 2007 to 
34 in 2012), while cases of serogroup Y gradually in-
creased (from 3 in 2007 to 17 in 2012). Furthermore, on 
analysing the distribution of serogroups by age-group, it 
was observed that serogroup B was the most frequently 
isolated in the younger age-groups. Indeed, considering 
the 762 cases for which age information was available, 
serogroup B accounted for 81.1% (77/95) of all cases 
occurring in the first year of life, 66.2% (92/139) of 
cases in 1-4-year-olds and 70.1% (54/77) in 5-9-year-
olds; in the other age-groups it accounted for about 50% 
of cases [18]. However, as demonstrated by Azzari et 
al. [19] by means of real-time PCR, in those countries 
(such as in Italy) [20] where only positive-isolate sam-
ples are counted as meningococcal cases, the incidence 
is largely underestimated. Furthermore, it is well known 
that culture-based methods have even lower sensitivity 
than molecular methods when the patient has been treat-
ed with antibiotics [21]. In addition, Azzari et al. found 
in their study that the case fatality rate was 13.2%, which 
is higher than the 5% rate recently reported in MenB in 
patients of any age [19, 22].
history of meningococcal vaccines 
against MenB
In the early 1900s, several attempts at using inacti-
vated vaccines containing whole bacterial cells were 
made  [23-27]. However, both these studies and sub-
sequent clinical trials revealed that whole inactivated 
vaccines were excessively reactogenic. Later vaccines 
obtained from meningococcal culture filtrate also yield-
ed contradictory results [28, 29]. The first successful 
meningococcal vaccines were obtained as a result of 
studies by Gotschlich et al., who were able to extract 
and purify high-molecular-weight meningococcal poly-
saccharides at the Walter Reed Army Institute [30, 31]. 
However, unlike the polysaccharides of serogroups A 
and C, the polysaccharide of serogroup B did not raise 
the production of antibodies on account of phenomena 
of immune tolerance. Thus, studies to prepare a vaccine 
against meningococcal B shifted to subcapsular antigens. 
The first and simplest approach was to use the meningo-
coccal outer membrane vesicles containing membrane 
proteins (OMVs) and lipopolysaccharide (LPS). Four 
different formulations of these vaccines were used in 
Cuba, Chile, Norway, New Zealand and France [32].
However, as subcapsular proteins are very variable, 
these vaccines proved to be of limited use in containing 
clonal epidemics. Therefore, in order to identify anti-
gens for development of universal MenB vaccine, stud-
ies were oriented towards the determination of the entire 
genome of a pathogenic strain of N. meningitidis type 
B (MC 58 strain) [33]. Thus, thanks to remarkable ad-
vances in bioinformatics and molecular biology, along 
with the knowledge acquired over the entire genome of 
MenB, a new science was born – “reverse vaccinology”. 
Indeed, the computer-assisted screening of the genome 
of the microorganism enabled the proteins that were the 
best candidates for a vaccine against MenB to be identi-
fied [34]. It was thus possible to identify about 600 open 
reading frames that were believed to express surface or 
exported proteins of MenB. Starting from these 600 pro-
teins, it was possible to express 350 in E. coli, which, 
after being purified, were able to elicit bactericidal an-
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tibodies in mice. Finally, through successive studies on 
rat and mouse models, the best components were found: 
Neisserial heparin binding antigen (NHBA), factor 
H binding protein (fHbp), Neisseria adhesion A (Na-
dA) [32]. The new universal MenB vaccine (4CMenB – 
Bexsero®) also contains the OMVs of the New Zealand 
strain NZ98/254.
Contemporarily, other researchers developed another 
new-generation MenB vaccine (rLP2086 – Trumem-
ba®), a preparation containing two representative vari-
ants of subfamilies A and B of fHbp [35-39].
Another approach pursued by scientists in order to de-
velop a vaccine for meningitis B was to improve vac-
cines containing antigens of the outer membrane. This 
approach is based on the ability of genetically modified 
MenB to express different subtypes of porin A. The lat-
est development of this vaccine contains 9 subtypes of 
PorA [40].
Availability of new MenB vaccines
Bexsero® has been approved and is available in Europe, 
the USA, Canada, Australia and Chile, and is currently 
under review in Brazil [41]. Trumemba® is currently 
approved only in the USA, for use in adolescents and 
young adults [42].
MenB vaccination policies
Vaccination strategies should be considered in terms of 
both collective prevention and individual prevention.
The natural history of meningococcal infections and 
invasive disease epidemiological trends clearly sug-
gest that: a) it is necessary to protect infants as early as 
possible; b) it is important to vaccinate adolescents and 
young adults, who are a risk group, as they constitute 
the reservoir of the microorganism and can transmit 
the pathogen to infant siblings. Moreover, in the indi-
vidual perspective, it is important to reach vulnerable 
subjects.
The best policy would be to vaccinate all subjects from 0 
to 18 years of age through an extensive campaign, as sug-
gested by the results achieved in the UK with the conju-
gate vaccine for meningococcus C [43]. When this is not 
economically sustainable, it is very important to study 
the conditions which regulate the spread of the disease. 
Mathematical models with simplified algorithms can 
provide the key to obtaining the maximum yield with 
the minimum of resources. The first question concerns 
how many subjects the sick person is able to infect [44]. 
Naturally, this will depend on the characteristics of dif-
fusivity of the pathogen, the number of subjects with 
whom the patient comes into contact, the number of sus-
ceptible, partially susceptible or protected individuals, 
and the period of time during which the subject is able to 
spread the disease. It is logical to imagine that, if a large 
number of subjects are protected, for example through 
vaccination, the pathogen will have difficulty spreading 
in the healthy population. If the proportion of vaccinees 
is high enough, it may be assumed that the patient can 
infect only a small number of people; if this number falls 
below 1, there is hope that the disease can be eliminated, 
as it will be impossible for the microrganism to circulate 
among humans. The mathematical modellers call this 
proportion the critical percentage of vaccination cov-
erage. The higher the critical percentage is, the harder 
it will be to eliminate the disease. Now, in the case of 
meningitis, this critical percentage is estimated to be not 
very high. Indeed, to calculate the critical percentage of 
coverage, it is necessary to know the value of the basic 
reproductive number (R0), which has been estimated to 
be approximately 1.36-1.4 [45] for meningococcal type 
C. It may be even lower for meningococcal type B [46]. 
If, however, we imagine that the value of R0 is between 
1.26-1.4 for MenB, we can calculate [47] that the criti-
cal percentage of coverage ranges from 26.5 to 28.6%. 
Furthermore, during our recent study [9], we did not find 
the carriage state for meningococcus C among young 
adults in a setting where a coverage rate for the conju-
gate vaccine against N. meningitidis of serogroup C is 
87% among children and 49% among adolescents [48].
It is also important to consider that herd immunity 
against N. meningitis C has been substantially achieved 
through vaccination with the conjugate vaccine. Indeed, 
Trotter et al. found that, although the protection pro-
vided by the vaccine is, theoretically limited in British 
infants immunised with conjugate vaccine this protec-
tion persisted over time. This was also in agreement with 
the decrease in meningococcal C carriers among young 
British adults after the 1999-2000 vaccination campaign 
[49, 50]. It could therefore be surmised that herd immu-
nity can be effectively induced by MenB vaccine, too.
Recently, the World Health Organization (WHO) drew 
up some criteria for the introduction of a new vaccine. 
The basic criteria concern: disease burden, efficacy, 
safety and quality of the vaccine, comparison with other 
interventions against the disease, economic and finan-
cial issues, fiscal impact, financial sustainability, vac-
cine presentation, supply availability, and programmatic 
strength [51].
The guidelines defined by the WHO are in line with 
the criteria of Health Technology Assessment (HTA), 
which can obviously be applied to vaccines, too. In-
deed, HTA is a method of multidisciplinary assessment 
that deals with analysing the technical, scientific, eco-
nomic, ethical, legal, social and organizational issues 
arising from the application of new technologies [52]. 
Thus, in order to insert a new vaccine into the vaccina-
tion schedule (free and active offer by National Health 
Service), it is necessary to conduct an HTA study [53]. 
Indeed, vaccines are to be regarded as any other medi-
cal technology [52]. In HTA evaluations, cost-effec-
tiveness studies assume great importance. In the spe-
cific case of Bexsero®, these have yielded contrasting 
results and there is still uncertainty as to whether MenB 
vaccination by means of the 4CmenB vaccine should 
be introduced in developed countries. Indeed, on 
evaluating the introduction of Bexsero® in England, 
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Christensen et al. concluded that vaccination would 
be cost-effective from the National Health Service 
(NHS) perspective at a cost of £9-£17 per dose  [54]. 
Subsequently, however, after re-evaluating the cost-
effectiveness of universal vaccination with Bexsero® 
in England could be cost-effective with a low vaccine 
price [55]. By contrast, the results of a study conducted 
in Italy by Capri et al. demonstrated the cost-effective-
ness of vaccination at a cost of € 60 per dose, from the 
societal perspective [56]. However, a study conducted 
by Tirani et al. in Italy concluded that, from the NHS 
perspective, the immunisation programme was unlike-
ly to be cost-effective [57].
We recently carried out a cost-effectiveness study of this 
issue (article submitted to Human Vaccines & Immu-
notherapeutics). Our results confirmed that, especially 
from the societal perspective, the vaccination of Italian 
infants is cost-effective; the study considered various 
scenarios and also took into account the fact that cases 
occurring in Italy are underestimated [19].
It is important to consider that economic studies on vac-
cinations can have some limitations and they often adopt 
conservative estimates as not considering the underesti-
mation of cases of illness and considering a short-term 
duration of protection. It is certain that 4CmenB stimu-
lates the immune memory as it is made from MenB sur-
face proteins. Indeed, it is well known that the protein 
antigens are much more immunogenic in comparison 
with the polysaccharidic ones even if the latter are con-
jugated.
The offer of MenB vaccination against  
in Italy
Eight Italian Regions and one Autonomous Province 
currently offer free vaccination for MenB to certain 
groups of people (Fig. 1). While Piedmont and Emilia 
Romagna offer it only to subjects at risk [58, 59], seven 
Regions and one autonomous Province offer it actively 
and free of charge for infants. Basilicata was the first 
Region to insert it into the childhood vaccination calen-
dar [60]. Subsequently, Puglia, Veneto, Friuli Venezia 
Giulia, Tuscany, Liguria, Sicilia and the Autonomous 
Province of Bolzano included it in their vaccination 
schedules [61-67].
The above-mentioned seven Regions and the Autono-
mous Province of Bolzano, following the possible vac-
cine schedules (Tab. I), display slight variations in the 
age at which vaccination is administered. Indeed, as can 
be seen in figure 2, most of the Regions start vaccina-
tion early, as most cases of MenB invasive disease occur 
within the first year of life; only Veneto and Friuli Ven-
ezia Giulia schedule vaccination to begin at 7 months. 
With regard to the booster dose, most of the Regions 
schedule this at the 15th month, while Basilicata and 
Tuscany provide a booster at the13th month. For the mo-
ment, there is no plan to offer active and free vaccination 
for teenagers.
Tab. I. Authorized vaccination schedules of Bexsero® (Novartis vac-
cines and diagnostics Limited. Bexsero® prescribing information. 
document available at: http://www.bexsero.co.uk/healthcare-pro-
fessional/pdfs/Bexsero%20pI.pdf. Accessed on 1st July 2015)
Age of ad-
ministration
Primary im-
munisation
Time interval 
between 
doses
Booster 
dose
From 2 to 
5 months
3 doses 
(0.5 ml)
At least 
1 month
One dose 
from 12 to 
23 months 
after primary 
immunisation
From 6 to 
11 months
2 doses 
(0.5 ml)
At least 
2 months
One dose in 
the 2nd year 
of life (at least 
2 months 
after primary 
immunisation)
From 12 to 
23 months
2 doses 
(0.5 ml)
At least 
2 months
One dose 
(from 12 to 
23 months 
after primary 
immunisation)
From 2 to 
10 months
2 doses 
(0.5 ml)
At least 2 
months
From 11 
months
2 doses 
(0.5 ml)
At least 2 
months
Fig. 1. Italian regions where menB vaccine is offer free vaccina-
tion (February 2015).
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Conclusions
Strategically, infants constitute the first class of subjects 
to be vaccinated, and the Regions which offer free vac-
cination are rightly oriented in this direction. Indeed, the 
incidence rate of meningococcal meningitis in Italian in-
fants under 1 year of age is 3.7 per 100,000, i.e. more than 
10 times higher than the overall rate of invasive meningo-
coccal diseases observed in Italy. Furthermore, serogroup 
B is more frequently detected among infants aged under 
1 year, accounting for 65% of the total [68]. Moreover, 
both in order to better protect (indirectly) new-borns and 
to achieve the best herd immunity, it would be very useful 
to vaccinate young adults. It is likely that a similar multi-
cohort strategy, even with relatively low coverage rates, 
could prevent the circulation of MenB.
Finally, the vaccination plans of the Italian Regions that 
offer vaccination for infants are appropriate to epide-
miological reality, although Veneto and Friuli Venezia 
Giulia should bring forward the time of vaccination.
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